Ad hoc-Mitteilungen

Unternehmensmeldungen

Zeit Titel
So LafargeHolcim Signs Net Zero Pledge with Science-Bas.
Sa Novartis Piqray® data show survival benefit for patients .
Sa Novartis reports late-breaking data from Phase III COMBI.
Do Novartis Produktionsstandort in Marburg geht an Biotech.
Mi Novartis Tafinlar® + Mekinist® demonstrates long-term, .
Mi Novartis reinforces commitment to patient access, pricin.
14.09.20 European Medicines Agency (EMA) approves safety label.
14.09.20 Novartis reports positive topline results from the first Pha.
11.09.20 Novartis data show early treatment with Mayzent® (sipon.
11.09.20 Novartis presents data at ACTRIMS-ECTRIMS for Kesim.
08.09.20 Novartis data at ACTRIMS-ECTRIMS highlight the strengt.
07.09.20 Novartis post hoc analysis shows high-dose Enerzair® .
01.09.20 Novartis announces ambitious ESG targets to increase .
30.08.20 Novartis new analysis shows high consistency in loweri.
29.08.20 Novartis announces positive results from Phase II study .
26.08.20 Novartis investigational novel STAMP inhibitor asciminib .
22.08.20 Novartis provides update on Phase III study evaluating in.
20.08.20 FDA approves Novartis Kesimpta® (ofatumumab), the fir.
20.08.20 Alcon and Actress Katherine McNamara Encourage Con.
18.08.20 Alcon Reports Second Quarter 2020 Results
18.08.20 Alcon Reports Second Quarter 2020 Results
17.08.20 Novartis announces US District Court for the District of D.
05.08.20 Novartis announces NEJM publication of Phase III ASCL.
05.08.20 Three UBS Advisors in the Greater New England Market .
04.08.20 Novartis announces Kymriah® meets primary endpoint .
03.08.20 Novartis Cosentyx® receives EU approval for first-line sy.
30.07.20 LafargeHolcim: Resilient H1 performance, full recovery i.
27.07.20 Sandoz announces plans for joint investment to help str.
24.07.20 Novartis Adakveo® receives positive CHMP opinion for th.
22.07.20 ABB Appoints Theodor Swedjemark as Chief Communic.
22.07.20 ABB to Launch Share Buyback Program
22.07.20 Q2 2020 Results
21.07.20 Alcon Survey Shows More Screen Time Causing Consu.
21.07.20 Alcon Survey Shows More Screen Time Causing Consu.
21.07.20 Novartis delivered strong H1 performance. FY 2020 guid.
21.07.20 Novartis erzielte im ersten Halbjahr eine starke Perform.
17.07.20 Alcon to Showcase Latest Innovations, Data at American.
17.07.20 Alcon to Showcase Latest Innovations, Data at American.
16.07.20 Novartis launches first-of-its-kind not-for-profit portfolio of.
15.07.20 Alcon Issues First Corporate Responsibility Report as In.
15.07.20 Alcon Issues First Corporate Responsibility Report as In.
14.07.20 Alcon Announces FDA Approval of the OTC Switch of Pat.
14.07.20 Alcon Announces FDA Approval of the OTC Switch of Pat.
07.07.20 Novartis receives EC approval for Enerzair® Breezhaler®.
02.07.20 Novartis resolves legacy litigation matters, finalizing settl.
01.07.20 Sandoz reviewing options after Federal Circuit upholds l.
29.06.20 Novartis receives simultaneous approval for five new pr.
26.06.20 Novartis Cosentyx® gains positive CHMP opinion for ped.
26.06.20 Novartis receives positive CHMP opinion for new Xolair®.
25.06.20 Novartis Resolves Legacy FCPA Investigations
    Nächste Nächste    

Newssuche


Schließen